HPV-16 E2 gene disruption and sequence variation in CIN 3 lesions and invasive squamous cell carcinomas of the cervix: relation to numerical chromosome abnormalities
暂无分享,去创建一个
[1] J. Berumen,et al. Asian‐American variants of human papillomavirus type 16 have extensive mutations in the E2 gene and are highly amplified in cervical carcinomas , 1999, International journal of cancer.
[2] J. Meissner. Nucleotide sequences and further characterization of human papillomavirus DNA present in the CaSki, SiHa and HeLa cervical carcinoma cell lines. , 1999, The Journal of general virology.
[3] C. Wheeler,et al. Human papillomavirus type 16 variant lineages characterized by nucleotide sequence analysis of the E5 coding segment and the E2 hinge region. , 1999, The Journal of general virology.
[4] C. Wheeler,et al. Human papillomavirus type 16 variant lineages characterized by nucleotide sequence analysis of the E 5 coding segment and the E 2 hinge region , 1999 .
[5] E. Androphy,et al. Crystal structure of the E2 DNA-binding domain from human papillomavirus type 16: implications for its DNA binding-site selection mechanism. , 1998, Journal of molecular biology.
[6] R. Holm,et al. Disruption of the E1 and E2 Reading Frames of HPV 16 in Cervical Carcinoma Is Associated with Poor Prognosis , 1998, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[7] T. R. Broker,et al. The Carboxyl-Terminal Region of the Human Papillomavirus Type 16 E1 Protein Determines E2 Protein Specificity during DNA Replication , 1998, Journal of Virology.
[8] C. Herrington,et al. Interphase cytogenetic evidence for distinct genetic pathways in the development of squamous neoplasia of the uterine cervix. , 1998, Laboratory investigation; a journal of technical methods and pathology.
[9] C. Cooper,et al. Identification of single amino acids in the human papillomavirus 11 E2 protein critical for the transactivation or replication functions. , 1998, Virology.
[10] C. H. Buckley,et al. Aetiology, pathogenesis, and pathology of cervical neoplasia. , 1998, Journal of clinical pathology.
[11] J. Dillner,et al. Identification of a cytotoxic T-lymphocyte epitope in the human papillomavirus type 16 E2 protein. , 1997, The Journal of general virology.
[12] M. Evans,et al. Basal cell tetrasomy in low-grade cervical squamous intraepithelial lesions infected with high-risk human papillomaviruses. , 1997, Cancer research.
[13] C. Meijer,et al. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings , 1997, Journal of clinical microbiology.
[14] C. Wheeler,et al. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective , 1997, Journal of virology.
[15] M. Frattini,et al. Abrogation of a mitotic checkpoint by E2 proteins from oncogenic human papillomaviruses correlates with increased turnover of the p53 tumor suppressor protein , 1997, The EMBO journal.
[16] J. Meissner. Sequencing Errors in Reference HPV Clones , 1997 .
[17] F. Wiklund,et al. Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer , 2006, International journal of cancer.
[18] P. Howley,et al. Suppression of cellular proliferation by the papillomavirus E2 protein , 1995, Journal of virology.
[19] C. M. Sanders,et al. Characterization of human papillomavirus type 16 E2 protein and subdomains expressed in insect cells. , 1995, Virology.
[20] L. Banks,et al. Mutations in the human papillomavirus type 16 E2 protein identify a region of the protein involved in binding to E1 protein. , 1995, The Journal of general virology.
[21] C. M. Sanders,et al. Kinetic and equilibrium binding studies of the human papillomavirus type-16 transcription regulatory protein E2 interacting with core enhancer elements. , 1994, Nucleic acids research.
[22] H. Bernard,et al. The human papillomavirus type 16 E2 transcription factor binds with low cooperativity to two flanking sites and represses the E6 promoter through displacement of Sp1 and TFIID , 1994, Journal of virology.
[23] J. Underwood. Diagnostic Molecular Pathology. A Practical Approach , 1993 .
[24] T. R. Broker,et al. Viral E1 and E2 proteins support replication of homologous and heterologous papillomaviral origins. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[25] P. Howley,et al. Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[26] M. Stanley,et al. Lack of immortalizing activity of a human papillomavirus type 16 variant DNA with a mutation in the E2 gene isolated from normal human cervical keratinocytes. , 1992, Oncogene.
[27] D. McCance,et al. Regions of human papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes , 1992, Journal of virology.
[28] D. Lowy,et al. The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture , 1991, Journal of virology.
[29] J. Dillner,et al. A synthetic peptide defines a serologic IgA response to a human papillomavirus-encoded nuclear antigen expressed in virus-carrying cervical neoplasia. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[30] P. Howley,et al. Transcriptional trans-activation by the human papillomavirus type 16 E2 gene product , 1987, Journal of virology.
[31] M. Braun,et al. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines , 1987, Journal of virology.
[32] P. Howley,et al. Transactivation of a bovine papilloma virus transcriptional regulatory element by the E2 gene product , 1985, Cell.
[33] P. Howley,et al. Transcriptional transActivation by the Human Papillomavirus Type 16 E 2 Gene Product , 2022 .